Vitro Biopharma, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2026 As of Jul 31, 2026	Q2 FY2026 As of Apr 30, 2026	Q1 FY2026 As of Jan 31, 2026	Q4 FY2025 As of Oct 31, 2025	Q3 FY2025 As of Jul 31, 2025	Q2 FY2025 As of Apr 30, 2025	Q1 FY2025 As of Jan 31, 2025	Q4 FY2024 As of Oct 31, 2024	Q3 FY2024 As of Jul 31, 2024	Q2 FY2024 As of Apr 30, 2024	Q1 FY2024 As of Jan 31, 2024	Q4 FY2023 As of Oct 31, 2023	Q3 FY2023 As of Jul 31, 2023	Q2 FY2023 As of Apr 30, 2023	Q1 FY2023 As of Jan 31, 2023	Q4 FY2015 As of Oct 31, 2015	Q3 FY2015 As of Jul 31, 2015	Q2 FY2015 As of Apr 30, 2015	Q1 FY2015 As of Jan 31, 2015	Q4 FY2014 As of Oct 31, 2014
ASSETS
Accounts receivable - related parties (Note B)
Cash
Accounts Receivable
Nonrelated Party
Related Party
Total accounts Receivable
Accounts Receivable – Related Party
Inventory
Prepaid Expense
Prepaid project costs
Deferred Offering Costs
Total Current Assets
Goodwill
Intangible Assets, Net
Deferred costs
Property and Equipment, Net
Patents, Net
Right of Use Asset – Operating Lease
Other Assets
Total Assets

LIABILITIES
Current maturities on capital lease obligation
Lines of credit
Accounts Payable
Nonrelated Party
Related Party
Total accounts Payable
Notes Payable
Deferred Revenue, Net
Accrued Liabilities
Nonrelated Party
Related Party
Total accrued Liabilities
Accrued Liabilities – Related Party
Other accrued liabilities
Advances and accrued interest payable to officer (Note B)
Advances and accrued interest payable to officer
Accrued payroll expenses
2021 Series Convertible Note Payable – Related Party
Accrued Interest Payable – Related Party
Note Subscription Payable
2024 Series Senior Secured Convertible Notes Payable – Stock Settled, Net
Derivative/Warrant Liability
Advance from investor
Accrued Interest – Related Party
Current Maturities of Capital Lease Obligations
Current Maturities of Operating Lease Obligations
Total Current Liabilities
Capital lease obligation
Capital Lease Obligations, Net of Current Portion
Operating Lease Obligation, Net of Current Portion
2021 Series Convertible Notes Payable – Related Party
Unsecured 6% Note Payable – Related Party
Unsecured 4% Note Payable – Related Party
2022 Series Convertible Notes Payable
2023 Series Convertible Notes Payable Derivative/Warrant Liability
2023 Series Convertible Notes Payable - Stock Settled, Net
2023 Series B Convertible Notes Payable – Stock Settled, Net
2025 Series Senior Secured Convertible Notes Payable – Stock Settled, Net
Long Term Accrued Interest Payable
Long Term Accrued Interest Payable – Related Party
Total Long-Term Liabilities
Total Liabilities

REDEEMABLE PREFERRED STOCK
Redeemable Preferred Stock
STOCKHOLDERS’ DEFICIT
Preferred Stock
Series A-1 Preferred Stock
Series A Preferred Stock
Total preferred Stock
Common stock, 19,230,770 Shares Authorized, par value $0.001, 4,517,651 and 4,460,535 Outstanding, respectively
Additional Paid in Capital
Services prepaid with common stock
Less Treasury Stock
Accumulated Deficit
Total Stockholders’ Deficit
Total Liabilities, Redeemable Preferred Stock and Stockholders’ Deficit

Comments